Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,904
  • Shares Outstanding, K 172,836
  • Annual Sales, $ 149,240 K
  • Annual Income, $ -17,910 K
  • 60-Month Beta 1.30
  • Price/Sales 0.87
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RIGL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.48
  • Most Recent Earnings -0.11 on 11/03/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 256.42% ( +105.34%)
  • Historical Volatility 64.08%
  • IV Percentile 99%
  • IV Rank 37.85%
  • IV High 647.37% on 11/11/22
  • IV Low 18.31% on 09/21/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 15,754
  • Open Int (30-Day) 15,546

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.14
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.15
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6679 +6.47%
on 11/09/22
0.8180 -13.07%
on 11/01/22
-0.0153 (-2.11%)
since 10/28/22
3-Month
0.6679 +6.47%
on 11/09/22
1.5950 -55.42%
on 09/02/22
-0.7589 (-51.63%)
since 08/26/22
52-Week
0.6400 +11.11%
on 06/13/22
3.5150 -79.77%
on 03/18/22
-2.0589 (-74.33%)
since 11/26/21

Most Recent Stories

More News
Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in The Lancet Haematology, which summarizes the Phase 1...

RIGL : 0.7111 (-5.30%)
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

RIGL : 0.7111 (-5.30%)
RXRX : 8.38 (-9.50%)
Rigel: Q3 Earnings Snapshot

Rigel: Q3 Earnings Snapshot

RIGL : 0.7111 (-5.30%)
Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of five posters highlighting data from the Company's...

RIGL : 0.7111 (-5.30%)
Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More

Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.

BIIB : 291.90 (-4.34%)
GILD : 85.21 (-1.22%)
VRTX : 315.30 (+0.74%)
RIGL : 0.7111 (-5.30%)
DICE : 33.20 (+1.97%)
Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs

Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.

DVAX : 11.93 (-3.32%)
LLY : 365.77 (+0.14%)
RIGL : 0.7111 (-5.30%)
BOLT : 1.3100 (-1.50%)
Pre-Market Brief: Stocks Retreat as Global Growth Concerns Persist

December S&P 500 futures (ESZ22) are trending down -0.86% this morning after three major US benchmark indices finished the regular session lower, with the Nasdaq posting its lowest close since July 2020,...

ESZ22 : 3,979.00 (+0.22%)
GIVN.Z.IX : 3,184.000 (-1.73%)
GRAB : 2.80 (-5.41%)
LEG : 35.11 (-1.85%)
MSFT : 241.76 (-2.32%)
SPCE : 4.76 (-6.67%)
RIGL : 0.7111 (-5.30%)
ZS : 136.72 (-1.46%)
Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has received guidance from the U.S. Food and Drug Administration (FDA)'s...

RIGL : 0.7111 (-5.30%)
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RIGL : 0.7111 (-5.30%)
CNCE : 4.99 (-1.77%)
Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the...

RIGL : 0.7111 (-5.30%)
FMTX : 20.01 (+0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

3rd Resistance Point 0.7907
2nd Resistance Point 0.7704
1st Resistance Point 0.7407
Last Price 0.7111
1st Support Level 0.6907
2nd Support Level 0.6704
3rd Support Level 0.6407

See More

52-Week High 3.5150
Fibonacci 61.8% 2.4167
Fibonacci 50% 2.0775
Fibonacci 38.2% 1.7383
Last Price 0.7111
52-Week Low 0.6400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar